Ascendis Pharma A (ASND) Notes Payables (2021 - 2025)
Historic Notes Payables for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to $771.6 million.
- Ascendis Pharma A's Notes Payables rose 1899.74% to $771.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $771.6 million, marking a year-over-year increase of 1899.74%. This contributed to the annual value of $659.0 million for FY2024, which is 5045.57% up from last year.
- Latest data reveals that Ascendis Pharma A reported Notes Payables of $771.6 million as of Q3 2025, which was up 1899.74% from $684.4 million recorded in Q2 2025.
- Over the past 5 years, Ascendis Pharma A's Notes Payables peaked at $771.6 million during Q3 2025, and registered a low of $8.0 million during Q4 2021.
- Its 5-year average for Notes Payables is $518.2 million, with a median of $649.5 million in 2024.
- As far as peak fluctuations go, Ascendis Pharma A's Notes Payables soared by 359146.39% in 2023, and later tumbled by 288.3% in 2025.
- Quarter analysis of 5 years shows Ascendis Pharma A's Notes Payables stood at $8.0 million in 2021, then surged by 48.28% to $11.9 million in 2022, then surged by 3591.46% to $438.0 million in 2023, then skyrocketed by 48.55% to $650.6 million in 2024, then grew by 18.59% to $771.6 million in 2025.
- Its Notes Payables was $771.6 million in Q3 2025, compared to $684.4 million in Q2 2025 and $656.5 million in Q1 2025.